Otrzymano: Brak danych
Zaakceptowano: Brak danych
Opublikowano online: 2012-08-11
Medicine and veterinary
The study was conducted on 40 women in the early postmenopausal period, aged 52.3±3.1 years with primary osteoporosis unmanageable in treatment, divided into 2 groups based on a randomized list. Group I (n-20) was administered orally fluoride 0.25 mg kg-1 24 h-1 with modified transdermal hormone therapy/HRT, and group II (n-20) was administered orally fluoride and supplement hormonal therapy (HST) in 21 therapeutic cycle. The serum concentrations of osteocalcin (OC), procollagen (PICP), insulin-like growth factor I (IGF-1), prolactin basic (PRL) and prolactin after metoclopramide (PRL/ MCP) 4 times by using radioimmunoassy methods, before treatment and after 1, 3, 12 months of treatment. Bone mineral density (BMD) L2 – L4 was determined before treatment and at 12 month with a dualenergy x-ray absorptiometry scanner (Lunar DPX-1Q). In group I women receiving fluoride and transdermal HRT IGF-1 increased significantly while the concentrations of OC and PICP significantly decreased after 3 and 12 months of treatment but no statistically significant changes in the PRL concentration occurred. In group II women receiving orally fluoride and HST, a significant decrease in the concentration of IGF-1, OC after 3 and 12 months and a significant increase in the concentration of PRL and PRL/ MCP after 1, 3 and 12 months of treatment compared with the baseline values appeared. The concentration of type I procolagen (PICP) showed no statistically significant changes. Increase in bone mineral density was statistically significant L1, L2 (p < 0.05), L3, L4 (p < 0.01) compared with the baseline in the group receiving transdermal HRT. In women receiving fluoride and orally HST increase in the bone mineral density for L1 and L2 was non-insignificant, whereas for L3 and L4 it was significantly higher compared with the baseline (p < 0.05).
Stanosz M., Stanosz S., Puchalski A. 2009. An assessment of the influence of fluoride, modified transdermal replacement hormone therapy and supplement hormone therapy on unmanageable osteoporosis in postmenopausal women. J. Elem. 14(3): 545-551.
osteoporosis, fluoride, osteocalcin, modified hormone replacement therapy, hormone supplement therapy